Epigenetics and functional genomics
In the last decade, genetic studies of psychiatric disorders have identified numerous genomic regions that harbor genetic variants which are associated with increased risk to develop a psychiatric disorder (e.g. schizophrenia or bipolar disorder). One of the main challenges for understanding the effect of these variants is to first determine which of the genetic variants or the genes in those regions that have a functional effect. Our group bridges Molecular Genetics and Functional Genomics.
Our main aim is to better annotate regions of genetic susceptibility to mental disorders in order to narrow and identify the genetic variants with potential functional effects to move towards functional genomics studies.
We are also developing projects with epigenetic tools and datasets to try to understand how the environment can influence the genetic susceptibility to develop psychiatric disorders. We aim to:
- Better annotate some candidate regions implicated in psychiatric disorders to move towards the functional characterization of these regions.
- Integrate environmental information with epigenetic and genetic information to understand the gene by environment in susceptibility to mental disorders.
We particularly focus on schizophrenia and bipolar disorder. For the environment effects, we are focusing first on the effect of cannabis. We use mostly biostatistics and bioinformatics tools for the analysis of datasets.
We generate our own datasets for some epigenetic markers in patients and we also use publically available datasets to investigate the relation between epigenetic marks and loci of susceptibility for psychiatric disorders.
We integrate different level of information in patients: Genetic, epigenetic, transcriptomics and environment data.
- Identifying allelic heterogeneity at the gene level across mental disorders.
- Cognition and imaging genetics: we participate in several large consortium efforts and have also a few in house projects.
- An epigenetic investigation of schizophrenia and bipolar disorder.
- Molecular mechanisms of cannabis exposure risk in patients with psychosis.
We are part of the K.G. Jebsen Center for Psychosis Research, headed by Ole A. Andreassen. Clinical and biological data are available in NORMENT (the TOP sample). We are part of several consortia for the identification of genetic factors for brain morphology (ENIGMA) and cognitive abilities (COGENT and CHARGE).
We collaborate with Prof. Lars Nyberg, at the University of Umeå on Brain Imaging Genetics. We collaborate with Prof Sven Cichon, University of Basel, Dr Per Hoffman, University of Basel and Life and Brain, Bonn, Prof Markus Nöthen, Life and Brain Centre, Bonn. We collaborate with Prof Jonathan Mill, University of Exeter, UK.
The research is funded by the Research Council of Norway, University of Bergen, K.G Jebsen Foundation and Dr. Einar Martens Foundation.